We describe acute severe hepatitis B virus (HBV) infection with liver failure requiring transplantation in a patient in Poland treated with acalabrutinib.

By clicking submit, I authorize Arcamax and its affiliates to: (1) use, sell, and share my information for marketing purposes, including cross-context behavioral advertising, as described in our Privacy Policy , (2) add to information that I provide with other information like interests inferred from web page views, or data lawfully obtained from data brokers, such as past purchase or location data, or publicly available data, (3) contact me or enable others to contact me by email or other means with offers for different types of goods and services, and (4) retain my information while I am engaging with marketing messages that I receive and for a reasonable amount of time thereafter.

By clicking submit, I authorize Arcamax and its affiliates to: (1) use, sell, and share my information for marketing purposes, including cross-context behavioral advertising, as described in our Privacy Policy , (2) add to information that I provide with other information like interests inferred from web page views, or data lawfully obtained from data brokers, such as past purchase or location data, or publicly available data, (3) contact me or enable others to contact me by email or other means with offers for different types of goods and services, and (4) retain my information while I am engaging with marketing messages that I receive and for a reasonable amount of time thereafter.

Plain Language SummaryThis study looked at how well patients with chronic hepatitis B were monitored when taking three common medications: entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF).

Plain Language SummaryThis study looked at how well patients with chronic hepatitis B were monitored when taking three common medications: entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF).